NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$20.5b

Last Updated

2021/04/13 23:15 UTC

Data Sources

Company Financials +

Executive Summary

CureVac N.V., a clinical-stage biopharmaceutical company, engages in developing various transformative medicines based on messenger ribonucleic acid (mRNA). More Details


Snowflake Analysis

Flawless balance sheet with exceptional growth potential.

Share Price & News

How has CureVac's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CVAC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: CVAC's weekly volatility (9%) has been stable over the past year.


Market Performance


7 Day Return

3.4%

CVAC

-1.2%

US Biotechs

1.3%

US Market


1 Year Return

n/a

CVAC

26.8%

US Biotechs

53.9%

US Market

Return vs Industry: Insufficient data to determine how CVAC performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how CVAC performed against the US Market.


Shareholder returns

CVACIndustryMarket
7 Day3.4%-1.2%1.3%
30 Day9.0%-3.7%2.8%
90 Day-2.6%-6.3%6.6%
1 Yearn/a28.5%26.8%56.6%53.9%
3 Yearn/a25.1%19.3%62.7%52.3%
5 Yearn/a42.7%31.9%120.5%95.9%

Long-Term Price Volatility Vs. Market

How volatile is CureVac's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is CureVac undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: CVAC ($95.65) is trading below our estimate of fair value ($1388.18)

Significantly Below Fair Value: CVAC is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: CVAC is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: CVAC is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CVAC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CVAC is overvalued based on its PB Ratio (19x) compared to the US Biotechs industry average (3.7x).


Future Growth

How is CureVac forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

79.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CVAC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: CVAC is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: CVAC's is expected to become profitable in the next 3 years.

Revenue vs Market: CVAC's revenue (80.6% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: CVAC's revenue (80.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CVAC's Return on Equity is forecast to be very high in 3 years time (68.3%).


Past Performance

How has CureVac performed over the past 5 years?

-15.3%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: CVAC is currently unprofitable.

Growing Profit Margin: CVAC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if CVAC's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare CVAC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CVAC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.3%).


Return on Equity

High ROE: CVAC has a negative Return on Equity (-14.05%), as it is currently unprofitable.


Financial Health

How is CureVac's financial position?


Financial Position Analysis

Short Term Liabilities: CVAC's short term assets (€915.5M) exceed its short term liabilities (€110.5M).

Long Term Liabilities: CVAC's short term assets (€915.5M) exceed its long term liabilities (€150.0M).


Debt to Equity History and Analysis

Debt Level: CVAC is debt free.

Reducing Debt: CVAC had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable CVAC has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: CVAC is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 76.7% per year.


Dividend

What is CureVac current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CVAC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CVAC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CVAC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CVAC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CVAC's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Franz-Werner Haas (50 yo)

1.08yrs

Tenure

€601,881

Compensation

Dr. Franz-Werner Haas, LLD, LLM, PhD, has been Chief Executive Officer of CureVac AG since June 2020 and has been its Chief Operating Officer since 2018 and also serves as its Member of Management Board. H...


CEO Compensation Analysis

Compensation vs Market: Franz-Werner's total compensation ($USD718.06K) is below average for companies of similar size in the US market ($USD10.98M).

Compensation vs Earnings: Franz-Werner's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: CVAC's management team is considered experienced (2.8 years average tenure).


Board Members

Experienced Board: CVAC's board of directors are considered experienced (5.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: CVAC only recently listed within the past 12 months.


Top Shareholders

Company Information

CureVac N.V.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: CureVac N.V.
  • Ticker: CVAC
  • Exchange: NasdaqGM
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$20.476b
  • Shares outstanding: 186.16m
  • Website: https://www.curevac.com

Number of Employees


Location

  • CureVac N.V.
  • Friedrich-Miescher-Strasse 15
  • Tübingen
  • Baden-Württemberg
  • 72076
  • Germany

Listings


Biography

CureVac N.V., a clinical-stage biopharmaceutical company, engages in developing various transformative medicines based on messenger ribonucleic acid (mRNA). Its lead proprietary programs include CV8102 tha...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/13 23:15
End of Day Share Price2021/04/13 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.